Literature DB >> 8630600

Pulmonary fibrosis deaths in the United States, 1979-1991. An analysis of multiple-cause mortality data.

D M Mannino1, R A Etzel, R G Parrish.   

Abstract

We sought to describe pulmonary fibrosis mortality in the United States from 1979 through 1991 by analyzing death certificate reports compiled by the National Center for Health Statistics. Of the 26,866,600 people who died during the study period, 107,292 had a diagnosis of pulmonary fibrosis listed on their death certificates. Among men, age-adjusted mortality rates increased from 48.6 per 1,000,000 in 1979 to 50.9 per 1,000,000 in 1991 and, among women, these rates increased from 21.4 per 1,000,000 in 1979 to 27.2 per 1,000,000 in 1991. Among both men and women rates were higher in older age strata than in younger age strata. Age-adjusted mortality rates were consistently higher among whites and people of races than blacks. The frequency with which pulmonary fibrosis was listed as the underlying cause of death increased from 40% in 1979 to 56% in 1991. Age-adjusted mortality rates varied by state, with lowest rates in the Midwest and Northeast, and the highest rates in the West and Southeast. We conclude that the age-adjusted rate of pulmonary fibrosis among decedents in the United States increased, and pulmonary fibrosis was listed as the underlying cause of death with increasing frequency, over the study period. We cannot determine whether the differences we detected between regions, sexes, and races are related to characteristics of the disease or problems in death certification and coding.

Entities:  

Mesh:

Year:  1996        PMID: 8630600     DOI: 10.1164/ajrccm.153.5.8630600

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  33 in total

Review 1.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis.

Authors:  D J Lederer; S M Arcasoy; R G Barr; J S Wilt; E Bagiella; F D'Ovidio; J R Sonett; S M Kawut
Journal:  Am J Transplant       Date:  2006-07-26       Impact factor: 8.086

3.  Influence of sex and disease severity on gene expression profiles in individuals with idiopathic pulmonary fibrosis.

Authors:  Sean P McGee; Hongmei Zhang; Wilfried Karmaus; Tara Sabo-Attwood
Journal:  Int J Mol Epidemiol Genet       Date:  2014-05-29

4.  miR-210 promotes IPF fibroblast proliferation in response to hypoxia.

Authors:  Vidya Bodempudi; Polla Hergert; Karen Smith; Hong Xia; Jeremy Herrera; Mark Peterson; Wajahat Khalil; Judy Kahm; Peter B Bitterman; Craig A Henke
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-06-20       Impact factor: 5.464

5.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

Review 6.  Idiopathic pulmonary fibrosis: The current status of its epidemiology, diagnosis, and treatment in China.

Authors:  Haibo Huang; Xiaonu Peng; Chongwen Zhong
Journal:  Intractable Rare Dis Res       Date:  2013-08

7.  Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease.

Authors:  D B Sprunger; A L Olson; T J Huie; E R Fernandez-Perez; A Fischer; J J Solomon; K K Brown; J J Swigris
Journal:  Eur Respir J       Date:  2011-07-07       Impact factor: 16.671

Review 8.  Antioxidants as potential therapeutics for lung fibrosis.

Authors:  Brian J Day
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

9.  Aortic carboxypeptidase-like protein is expressed in fibrotic human lung and its absence protects against bleomycin-induced lung fibrosis.

Authors:  Scott L Schissel; Sarah E Dunsmore; Xiaoli Liu; Robert W Shine; Mark A Perrella; Matthew D Layne
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

Review 10.  The epidemiology of interstitial lung disease and its association with lung cancer.

Authors:  G Raghu; F Nyberg; G Morgan
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.